Systematic review finds oral JAK inhibitors improve refractory rosacea, suggesting a new treatment avenue.
Oral JAK inhibitors show promising potential as a therapeutic option for refractory rosacea. However, given the small sample size and single-arm design, these findings are exploratory. Large-scale randomized controlled trials are urgently needed to validate these findings and guide stratified treatment.
No takes yet. Share an insight, caveat, or question.
Peng et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: